Last reviewed · How we verify

AZD3759 — Competitive Intelligence Brief

AZD3759 (AZD3759) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: EGFR inhibitor. Area: Oncology.

phase 2 EGFR inhibitor EGFR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AZD3759 (AZD3759) — Guangdong Association of Clinical Trials. AZD3759 is a small molecule inhibitor of the EGFR pathway.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AZD3759 TARGET AZD3759 Guangdong Association of Clinical Trials phase 2 EGFR inhibitor EGFR
Rybrevant AMIVANTAMAB Johnson & Johnson marketed EGFR, MET 2021-01-01
NERATINIB NERATINIB marketed EGFR, HER2, HER4 2017-01-01
Inlyta Axitinib Pfizer marketed Receptor tyrosine kinase inhibitor Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3 2012-01-01
REGORAFENIB REGORAFENIB marketed RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R 2012-01-01
PONATINIB HYDROCHLORIDE PONATINIB HYDROCHLORIDE marketed ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3 2012-01-01
PAZOPANIB PAZOPANIB marketed Kinase Inhibitor [EPC] VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-ɑ, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms 2009-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (EGFR inhibitor class)

  1. Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 drug in this class
  2. Association pour la Recherche sur le Temps Biologique et la Chronothérapie · 1 drug in this class
  3. Guangdong Association of Clinical Trials · 1 drug in this class
  4. Hoffmann-La Roche · 1 drug in this class
  5. Janssen Research & Development, LLC · 1 drug in this class
  6. Shanghai Henlius Biotech · 1 drug in this class
  7. Sheba Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD3759 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd3759. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: